News Center
The new track for antifungal agents has begun.
Release time:
2024-06-06
Recently, the wholly-owned subsidiary of Livzon Pharmaceutical Group Inc., Livzon Group Livzon Pharmaceutical Factory (hereinafter referred to as "Livzon Pharmaceutical"), jointly announced with Shenzhen Xianggen Biotechnology Co., Ltd. (hereinafter referred to as "Xianggen Biotechnology"), which focuses on innovative drugs for antifungal infections and oral cyclic peptide innovation drug platforms, that both parties have reached a strategic cooperation on SG1001 and signed a Greater China equity transaction agreement.
According to the agreement, Livzon Pharmaceutical will obtain exclusive research and development, production, and commercialization rights for all developable dosage forms and indications of SG1001 in the Greater China region (mainland China, Macau, Hong Kong, and Taiwan) for antifungal and other therapeutic areas, while Xianggen Biotechnology will retain research and development, production, and commercialization rights for SG1001 outside the cooperation area.
SG1001 is a fungal dhodh inhibitor developed by Xianggen Biotechnology with independent intellectual property rights and a new structure, classified as a category 1 innovative chemical drug. This project won third place in the 14th China Shenzhen Innovation and Entrepreneurship Competition.
Dihydroorotate dehydrogenase (dhodh) is a redox enzyme that catalyzes the de novo biosynthesis of pyrimidines, converting dihydroorotic acid into orotic acid, and is a key enzyme in the biosynthesis of fungal pyrimidines. SG1001 tablets selectively inhibit fungal dhodh, thereby inhibiting the biosynthesis of fungal pyrimidines, affecting cell wall formation, and inhibiting fungal growth. Currently, this product has obtained domestic clinical trial approval and is intended for the treatment of invasive fungal diseases.
Mr. Tang Yanggang, Executive Director and President of Livzon Pharmaceutical, stated: "Livzon continues to increase investment in innovative drug research and development, and cooperation with Xianggen Biotechnology can further deepen Livzon's layout in the new drug research and development pipeline in the field of anti-infection. We are optimistic about the future market potential of SG1001 and will accelerate the clinical development of this product to achieve commercialization as soon as possible."
Mr. Huang Shenghong, Chairman of Xianggen Biotechnology, stated: "We are very pleased to cooperate with Livzon. We believe that under Livzon's leadership, the SG1001 project can accelerate the clinical trial and commercialization process, providing a new drug for patients with fungal infections in our country as soon as possible, bringing new hope for patients' treatment and life health, and will certainly accelerate the internationalization process of SG1001."
Fungal infections are known as hidden killers and are a significant cause of death for patients with tumors, AIDS, organ transplants, and more. Among them, invasive aspergillosis is a severe deep fungal infection with a very poor prognosis, often occurring in the lungs, and has a high mortality rate. More than 2 million people worldwide develop invasive aspergillosis each year against the background of chronic obstructive pulmonary disease, severe infections, lung cancer, or hematologic malignancies, with a crude annual mortality rate of 85.2%. Current first-line treatments are often limited in efficacy and have serious adverse reactions, and resistance is becoming increasingly easy to acquire. Long-term neutropenia, allogeneic hematopoietic stem cell transplantation, hematologic malignancies, solid organ transplantation, use of glucocorticoids, advanced AIDS, chronic granulomatous disease, and the use of immunosuppressants are considered major factors that induce invasive aspergillosis, among which long-term neutropenia, allogeneic hematopoietic stem cell transplantation, and hematologic malignancies are high-risk factors.
Related Information